Comparative Pharmacology
Head-to-head clinical analysis: SPRX 105 versus VIZZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SPRX 105 versus VIZZ.
SPRX-105 vs VIZZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SPRX-105 is a dual dopamine D2 and serotonin 5-HT1A receptor partial agonist, functioning as a postsynaptic antagonist and presynaptic agonist at D2 receptors, and as a partial agonist at 5-HT1A receptors, modulating neurotransmitter release.
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
SPRX-105 is administered orally at a dose of 50 mg once daily.
80 mg orally once daily
None Documented
None Documented
12-15 hours in healthy adults; extended to 24-30 hours in renal impairment.
Terminal elimination half-life is 18-24 hours. Steady-state is reached within 4-5 days; accumulation may occur in renal impairment.
Primarily renal (70-80% unchanged) with 15-20% biliary/fecal elimination.
Primarily hepatic metabolism with renal excretion of metabolites. Approximately 60% of a dose is excreted in urine as metabolites, 30% in feces, and <5% unchanged.
Category C
Category C
Unknown
Unknown